Figure 1.
LRP-IV clears mouse endogenous brain Aβ improves function and clears human brain Aβ in APP+/sw mice. (a,b) Brain levels (a) and total plasma levels (b) of mouse endogenous Aβ40 and Aβ42 in vehicle-treated (white) and LRP-IV-treated (intravenously for 5 d, 20 µg/day) mice (black) Values are means ± s.e.m., n = 3–5 mice per group. (c) Percent increase in cerebral blood flow (CBF) in response to whisker stimulation in littermate controls (gray) and APP+/sw mice treated with vehicle (white) or LRP-IV (black). (d–f) Operant learning at day 1 and 2 (d), novel object location (e) and novel object recognition (f) expressed as percentage exploratory preference in littermate controls (gray) and APP+/sw mice treated with vehicle (white) or LRP-IV (black). (g,h) Aβ40 and Aβ42 levels in hippocampus (g) and cortex (h) of APP+/sw mice treated with vehicle or LRP-IV. In c–h, LRP-IV (40 µg per kg body weight per day) was administered intraperitioneally for 3 months beginning at age 6 months. Values are means ± s.e.m., n = 8 mice per group. All procedures with wild-type mice and APP+/sw mice were according to US NIH guidelines approved by the University Committee on Animal Resources, University of Rochester.